Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Sep 15;60(12):1012–1018. doi: 10.1136/thx.2005.045260

Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

P Howarth 1, K Babu 1, H Arshad 1, L Lau 1, M Buckley 1, W McConnell 1, P Beckett 1, A Al 1, A Chauhan 1, S Wilson 1, A Reynolds 1, D Davies 1, S Holgate 1
PMCID: PMC1747263  PMID: 16166100

Abstract

Background: Tumour necrosis factor α (TNFα) is a major therapeutic target in a range of chronic inflammatory disorders characterised by a Th1 type immune response in which TNFα is generated in excess. By contrast, asthma is regarded as a Th2 type disorder, especially when associated with atopy. However, as asthma becomes more severe and chronic, it adopts additional characteristics including corticosteroid refractoriness and involvement of neutrophils suggestive of an altered inflammatory profile towards a Th1 type response, incriminating cytokines such as TNFα.

Methods: TNFα levels in bronchoalveolar lavage (BAL) fluid of 26 healthy controls, 42 subjects with mild asthma and 20 with severe asthma were measured by immunoassay, and TNFα gene expression was determined in endobronchial biopsy specimens from 14 patients with mild asthma and 14 with severe asthma. The cellular localisation of TNFα was assessed by immunohistochemistry. An open label uncontrolled clinical study was then undertaken in 17 subjects with severe asthma to evaluate the effect of 12 weeks of treatment with the soluble TNFα receptor-IgG1Fc fusion protein, etanercept.

Results: TNFα levels in BAL fluid, TNFα gene expression and TNFα immunoreative cells were increased in subjects with severe corticosteroid dependent asthma. Etanercept treatment was associated with improvement in asthma symptoms, lung function, and bronchial hyperresponsiveness.

Conclusions: These findings may be of clinical significance in identifying TNFα as a new therapeutic target in subjects with severe asthma. The effects of anti-TNF treatment now require confirmation in placebo controlled studies.

Full Text

The Full Text of this article is available as a PDF (152.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson Paul J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005 Apr;34(5 SUPPL1):19–22. doi: 10.1016/j.semarthrit.2005.01.005. [DOI] [PubMed] [Google Scholar]
  2. Antonicelli L., Bucca C., Neri M., De Benedetto F., Sabbatani P., Bonifazi F., Eichler H. G., Zhang Q., Yin D. D. Asthma severity and medical resource utilisation. Eur Respir J. 2004 May;23(5):723–729. doi: 10.1183/09031936.04.00004904. [DOI] [PubMed] [Google Scholar]
  3. Bradding P., Roberts J. A., Britten K. M., Montefort S., Djukanovic R., Mueller R., Heusser C. H., Howarth P. H., Holgate S. T. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994 May;10(5):471–480. doi: 10.1165/ajrcmb.10.5.8179909. [DOI] [PubMed] [Google Scholar]
  4. Brightling Christopher E., Bradding Peter, Symon Fiona A., Holgate Stephen T., Wardlaw Andrew J., Pavord Ian D. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002 May 30;346(22):1699–1705. doi: 10.1056/NEJMoa012705. [DOI] [PubMed] [Google Scholar]
  5. Britten K. M., Howarth P. H., Roche W. R. Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem. 1993 Sep;68(5):271–280. doi: 10.3109/10520299309105629. [DOI] [PubMed] [Google Scholar]
  6. Broide D. H., Lotz M., Cuomo A. J., Coburn D. A., Federman E. C., Wasserman S. I. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992 May;89(5):958–967. doi: 10.1016/0091-6749(92)90218-q. [DOI] [PubMed] [Google Scholar]
  7. Busse W. W., Banks-Schlegel S., Wenzel S. E. Pathophysiology of severe asthma. J Allergy Clin Immunol. 2000 Dec;106(6):1033–1042. doi: 10.1067/mai.2000.111307. [DOI] [PubMed] [Google Scholar]
  8. Chai H., Farr R. S., Froehlich L. A., Mathison D. A., McLean J. A., Rosenthal R. R., Sheffer A. L., Spector S. L., Townley R. G. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol. 1975 Oct;56(4):323–327. doi: 10.1016/0091-6749(75)90107-4. [DOI] [PubMed] [Google Scholar]
  9. Culy Christine R., Keating Gillian M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 2002;62(17):2493–2537. doi: 10.2165/00003495-200262170-00013. [DOI] [PubMed] [Google Scholar]
  10. Djukanović R., Wilson J. W., Lai C. K., Holgate S. T., Howarth P. H. The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):772–777. doi: 10.1164/ajrccm/143.4_Pt_1.772. [DOI] [PubMed] [Google Scholar]
  11. Feldmann Marc, Maini Ravinder N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003 Oct;9(10):1245–1250. doi: 10.1038/nm939. [DOI] [PubMed] [Google Scholar]
  12. Juniper E. F., O'Byrne P. M., Guyatt G. H., Ferrie P. J., King D. R. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902–907. doi: 10.1034/j.1399-3003.1999.14d29.x. [DOI] [PubMed] [Google Scholar]
  13. Kay A. B. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001 Jan 4;344(1):30–37. doi: 10.1056/NEJM200101043440106. [DOI] [PubMed] [Google Scholar]
  14. Kips J. C., Tavernier J., Pauwels R. A. Tumor necrosis factor causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):332–336. doi: 10.1164/ajrccm/145.2_Pt_1.332. [DOI] [PubMed] [Google Scholar]
  15. Kodera Masanari, Hasegawa Minoru, Komura Kazuhiro, Yanaba Koichi, Takehara Kazuhiko, Sato Shinichi. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005 Sep;52(9):2889–2896. doi: 10.1002/art.21257. [DOI] [PubMed] [Google Scholar]
  16. Koranteng R. D., Swindle E. J., Davis B. J., Dearman R. J., Kimber I., Flanagan B. F., Coleman J. W. Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580. Clin Exp Immunol. 2004 Jul;137(1):81–87. doi: 10.1111/j.1365-2249.2004.02510.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Li Kam Wa T. C., Mansur A. H., Britton J., Williams G., Pavord I., Richards K., Campbell D. A., Morton N., Holgate S. T., Morrison J. F. Association between - 308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma. Clin Exp Allergy. 1999 Sep;29(9):1204–1208. doi: 10.1046/j.1365-2222.1999.00638.x. [DOI] [PubMed] [Google Scholar]
  18. Ming W. J., Bersani L., Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 1987 Mar 1;138(5):1469–1474. [PubMed] [Google Scholar]
  19. Noguchi Emiko, Yokouchi Yukako, Shibasaki Masanao, Inudou Michharu, Nakahara Satoko, Nogami Tetsuo, Kamioka Masashi, Yamakawa-Kobayashi Kimiko, Ichikawa Kunio, Matsui Akira. Association between TNFA polymorphism and the development of asthma in the Japanese population. Am J Respir Crit Care Med. 2002 Jul 1;166(1):43–46. doi: 10.1164/rccm.2110052. [DOI] [PubMed] [Google Scholar]
  20. Peck Robert, Fitzgerald Daniel W., Liautaud Bernard, Deschamps Marie Marcelle, Verdier Rose Irene, Beaulieu Marie Eugene, GrandPierre Reynold, Joseph Patrice, Severe Patrice, Noel Francine. The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985-2000. J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):470–475. doi: 10.1097/00126334-200308010-00007. [DOI] [PubMed] [Google Scholar]
  21. Pizzichini E., Pizzichini M. M., Kidney J. C., Efthimiadis A., Hussack P., Popov T., Cox G., Dolovich J., O'Byrne P., Hargreave F. E. Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. Eur Respir J. 1998 Apr;11(4):828–834. doi: 10.1183/09031936.98.11040828. [DOI] [PubMed] [Google Scholar]
  22. Thomas P. S., Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax. 2002 Sep;57(9):774–778. doi: 10.1136/thorax.57.9.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Thomas P. S. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol. 2001 Apr;79(2):132–140. doi: 10.1046/j.1440-1711.2001.00980.x. [DOI] [PubMed] [Google Scholar]
  24. Thomas P. S., Yates D. H., Barnes P. J. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995 Jul;152(1):76–80. doi: 10.1164/ajrccm.152.1.7599866. [DOI] [PubMed] [Google Scholar]
  25. Tillie-Leblond I., Pugin J., Marquette C. H., Lamblin C., Saulnier F., Brichet A., Wallaert B., Tonnel A. B., Gosset P. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med. 1999 Feb;159(2):487–494. doi: 10.1164/ajrccm.159.2.9805115. [DOI] [PubMed] [Google Scholar]
  26. Ulbrich Holger, Eriksson Einar E., Lindbom Lennart. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci. 2003 Dec;24(12):640–647. doi: 10.1016/j.tips.2003.10.004. [DOI] [PubMed] [Google Scholar]
  27. Van den Brande Jan M. H., Braat Henri, van den Brink Gijs R., Versteeg Henri H., Bauer Christiaan A., Hoedemaeker Inge, van Montfrans Catherine, Hommes Daan W., Peppelenbosch Maikel P., van Deventer Sander J. H. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003 Jun;124(7):1774–1785. doi: 10.1016/s0016-5085(03)00382-2. [DOI] [PubMed] [Google Scholar]
  28. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  29. Zuany-Amorim Claudia, Manlius Corinne, Dalum Iben, Jensen Martin R., Gautam Anand, Pay Graham, Mouritsen Søren, Walker Christoph. Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol. 2004 Jan 26;133(2):154–163. doi: 10.1159/000076441. [DOI] [PubMed] [Google Scholar]
  30. ten Brinke A., Zwinderman A. H., Sterk P. J., Rabe K. F., Bel E. H. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001 Sep 1;164(5):744–748. doi: 10.1164/ajrccm.164.5.2011026. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES